Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryApr 3, 2018	Dicerna to Present at the H.C. Wainwright Global Life Sciences Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will provide a...	View HTML
Toggle SummaryMar 9, 2018	Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will provide a corporate overview at...	View HTML Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium 10.3 KB
Toggle SummaryMar 8, 2018	Dicerna Reports Fourth Quarter and Year End 2017 Financial and Operating Results and Provides Corporate Update Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the fourth quarter...	View HTML Dicerna Reports Fourth Quarter and Year End 2017 Financial and Operating Results and Provides Corporate Update 38.1 KB
Toggle SummaryMar 5, 2018	Dicerna to Present at the Cowen and Company 38th Annual Health Care Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present at the Cowen and Company...	View HTML Dicerna to Present at the Cowen and Company 38th Annual Health Care Conference 11.1 KB
Toggle SummaryMar 1, 2018	Dicerna to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 8, 2018 CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and full year 2017 financial results after market close on...	View HTML Dicerna to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 8, 2018 11.3 KB
Toggle SummaryFeb 6, 2018	Dicerna to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will participate in two investor...	View HTML Dicerna to Participate in Upcoming Investor Conferences 14.2 KB
Toggle SummaryJan 23, 2018	Dicerna to Present at Noble Capital Markets' NobleCon14 CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present at NobleCon14 - Noble...	View HTML Dicerna to Present at Noble Capital Markets' NobleCon14 11 KB
Toggle SummaryDec 14, 2017	Dicerna Announces Pricing of Follow-On Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) ("Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today the pricing of its underwritten registered public offering of 5,714,286 shares of its common stock...	View HTML Dicerna Announces Pricing of Follow-On Public Offering of Common Stock 17.4 KB
Toggle SummaryDec 13, 2017	Dicerna Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc . (NASDAQ:DRNA) ("Dicerna" or the "Company"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today the commencement of a proposed underwritten public offering of shares of its...	View HTML Dicerna Announces Proposed Public Offering of Common Stock 16.1 KB
Toggle SummaryDec 7, 2017	Dicerna Announces First Human Dosed in Phase 1 Clinical Trial of DCR-PHXC for Treatment of All Forms of Primary Hyperoxaluria Clinical Proof-of-Concept Data for First GalXC™ RNAi Product Candidate Expected in Second Half of 2018 CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc . (NASDAQ:DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced the dosing of the first human in...	View HTML Dicerna Announces First Human Dosed in Phase 1 Clinical Trial of DCR-PHXC for Treatment of All Forms of Primary Hyperoxaluria 26.9 KB

|

Press Releases